CD38

Product List

Creative Biolabs provides a full range of CD38 CAR-related products to aid in global customers’ CART projects. Feel free to explore and inquire about the specific product you need.

Background

CD38 is a glycoprotein molecule with enzyme activity. As an enzyme, it has NAD-consumption and intracellular signaling activities, or cell adhesion receptor activity. CD38 is abundant on the surface of many immune cells, including B lymphocytes CD4+ lymphocytes, CD8+ lymphocytes, and natural killer cells. The role of CD38 is involved in several processes, including regulation of cell differentiation of immune cells, and effector function during inflammation. Studies have shown that CD38 plays an important role in the pathogenesis and prognosis of many diseases, such as multiple myeloma, chronic lymphocytic leukemia, and human immunodeficiency virus infection. And development of targeting CD38 CAR-T provides a promising solution for these diseases.

Fig.1 Scheme of CD38 CAR-T design.¹

Associated Diseases

• Multiple myeloma
• Chronic lymphocytic leukemia (CLL)
• Acute myeloid leukemia (AML)
• Others

Anti-CD38 CAR-T Services

Anti-CD38 CAR-T In Vitro Assays

Anti-CD38 CAR-T Expression Test

The detection of CAR expression provides a reference for the evaluation of the transfection efficiency in the early stage of CAR-T development. Creative Biolabs has developed several robust and sensitive CAR detection reagents with different fluorescence labels to facilitate customers’ use. Meanwhile, we also provide a complete set of expression detection assays to evaluate target-specific CAR expression.

Fig.2 The CD38 CAR integration copy number detection of primary T cell after transduction by RT-qPCR.¹

Anti-CD38 CAR-T Cell Proliferation Test

Creative Biolabs provides various CAR-T proliferation test services to evaluate the amplification capacity of CAR-T cells, such as carboxyfluorescein succinimidyl ester (CFSE)-based cell proliferation assay by flow cytometry to test the proliferation ability of CART cells when co-cultured with target cells.

Fig.3 Proliferation test of CD38 CAR-T cells by the CFSE-based methods.¹

Phenotype Analysis of Anti-CD38 CAR-T Cell

To investigate the target-dependent activation and expansion of CAR-T cells, we have established a full list of testing services to assess the function of CAR-T cells, including the phenotype analysis by expression test of CD69, CD25, and HLA-DR.

Fig.4 The expression test of activation markers on CD38 CAR-T cells.²

Anti-CD38 CAR-T Cytokine Release Test

Creative Biolabs provides comprehensive cytokine analysis services to evaluate the cytokines-releasing capability of CART cells co-cultured with target cells, including but not limited to the following cytokines: TNFa, IFNg, IL-2, Granzyme B, IL-10, IL-6.

Fig.5 Cytokines secretion analysis of anti CD38 CAR-T cells co-cultured with RPMI-GFP-Luc target cells by CBA kit.¹

Anti-CD38 CAR-T In Vitro Cytotoxicity Assay

Luciferase assay and lactate dehydrogenase (LDH) assay are extremely useful as a detection method to evaluate cell proliferation of CD38 CAR-T cells.

For in vitro tumor-killing tests, we offer a variety of approaches for customers to choose from:

• Luciferase-based cytotoxicity assay

Fig.6 In vitro tumor killing test of CD38 CAR-T cells against RPMI-GFP-Luc target cells or Raji-Luc target cells by luciferase assay.¹

• Imaging system-based cytotoxicity assay

Fig.7 In vitro cytotoxicity assay of CD38 CAR-T cells against RPMI-GFP-Luc target cells at 1:1 E:T ratio measured by imaging system.¹

• Flow cytometry-based cytotoxicity assay

Fig.8 In vitro anti-tumor analysis of CD38 CAR-T cells against 4 different target cells by flow cytometry.1

Anti-CD38 CAR-T In Vivo Assays

Anti-CD38 CAR-T Cell Therapy Animal Models

Creative Biolabs offers a variety of animal models to assist clients’ projects, including cell line-derived xenografted (CDX) models, and patient-derived xenografted (PDX) models. At the same time, leveraging our years of experience in CART fields, we provide various optimal experiment schemes for customer reference.

Fig.9 Experimental design of in vivo anti-tumor assessment for CD38 CAR-T.¹

Efficacy Test of Anti-CD38 CAR-T

Comprehensive efficacy test and toxicity evaluation services are also available in Creative Biolabs, please don't hesitate to reach out to us for further information and offerings regarding CD38 CAR-T services and products.

Fig.10 In vivo efficacy assessment of CD38 CAR-T in a mouse xenograft tumor model.¹

References

1. Li, Xiaorui.; et al. "Characterization of the therapeutic effects of novel chimeric antigen receptor T cells targeting Cd38 on multiple myeloma." Frontiers in Oncology 11 (2021): 703087.
2. Li, Hongwen.; et al. "A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma." Cancer Medicine (2023).